-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3312 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3312 in Solid Tumor Drug Details:JAB-3312 is under development for the treatment of breast cancer, colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-21822 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-21822 in Colorectal Cancer Drug Details:JAB-21000 is under development for the treatment of colorectal cancer (CRC),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3312 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3312 in Colorectal Cancer Drug Details:JAB-3312 is under development for the treatment of breast cancer, colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3068 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3068 in Solid Tumor Drug Details:JAB-3068 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-8263 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. JAB-8263 in Solid Tumor Drug Details: JAB-8263 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-2485 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-2485 in Solid Tumor Drug Details:JAB-2485 is under development for the treatment of RB1 deficient tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3068 in Esophageal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3068 in Esophageal Cancer Drug Details:JAB-3068 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-21822 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.JAB-21822 in Solid TumorDrug Details:JAB-21000 is under development for the treatment of colorectal cancer (CRC), non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3312 in Pancreatic Ductal Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3312 in Pancreatic Ductal CarcinomaDrug Details:JAB-3312 is under development for the treatment of breast cancer, colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-21822 in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.JAB-21822 in Pancreatic Ductal AdenocarcinomaDrug Details:JAB-21000 is under development for the treatment of colorectal cancer (CRC),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-2485 in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-2485 in Small-Cell Lung Cancer Drug Details:JAB-2485 is under development for the treatment of RB1 deficient...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-21822 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-21822 in Non-Small Cell Lung Cancer Drug Details:JAB-21000 is under development for the treatment of colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3312 in Esophageal Squamous Cell Carcinoma (ESCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3312 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:JAB-3312 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3312 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3312 in Non-Small Cell Lung Cancer Drug Details:JAB-3312 is under development for the treatment of breast...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3068 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3068 in Non-Small Cell Lung Cancer Drug Details:JAB-3068 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-2485 in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-2485 in Triple-Negative Breast Cancer (TNBC) Drug Details:JAB-2485 is under development for the treatment of RB1...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3068 in Esophageal Squamous Cell Carcinoma (ESCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3068 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:JAB-3068 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3068 in Head And Neck Cancer Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3068 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details:JAB-3068 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3312 in Head And Neck Cancer Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3312 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details:JAB-3312 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SPH-6516 in Liposarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SPH-6516 in Liposarcoma Drug Details: SPH-6516 is under development for the treatment of solid tumors...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.